Revvity (RVTY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Revvity (RVTY) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Revvity (RVTY) Surpasses Q2 Earnings and Revenue Estimates
Revvity (RVTY) came out with quarterly earnings of $1.18 per share, beating the Zacks Consensus Estimate of $1.14 per share. This compares to earnings of $1.22 per share a year ago.
Revvity Stock Tumbles After Earnings. What's Dragging on the Shares.
The health sciences company posts better-than-expected adjusted earnings and revenue but trims its guidance.
Why Revvity (RVTY) is Poised to Beat Earnings Estimates Again
Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Revvity Q2 Preview: Can Strong Segments Deliver an Earnings Beat?
RVTY is likely to see another earnings beat as Diagnostics momentum and Signals Software growth offset tariff headwinds.
Wall Street's Insights Into Key Metrics Ahead of Revvity (RVTY) Q2 Earnings
Beyond analysts' top-and-bottom-line estimates for Revvity (RVTY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.
Revvity (RVTY) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Revvity (RVTY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RVTY Stock Falls Despite the Latest Launch of Automated Instrument
Revvity unveils IDS i20, a fully automated immunodiagnostics platform designed to enhance lab efficiency and expand specialty testing.
RVTY Rises as Q1 Earnings & Sales Beat Estimates, '25 Sales View Up
Revvity's first-quarter results showcase strong growth in Diagnostics business, along with recovery in Life Sciences segmental sales.
Revvity, Inc. (RVTY) Q1 2025 Earnings Call Transcript
Revvity, Inc. (NYSE:RVTY ) Q1 2025 Earnings Conference Call April 28, 2025 8:00 AM ET Company Participants Steve Willoughby - Senior Vice President, Investor Relations Prahlad Singh - President & Chief Executive Officer Max Krakowiak - Senior Vice President & Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Dan Brennan - TD Cowen Matt Sykes - Goldman Sachs Vijay Kumar - Evercore ISI Catherine Schulte - Baird Daniel Arias - Stifel Dan Leonard - UBS Luke Sergott - Barclays Tycho Peterson - Jefferies Operator Welcome everyone to Q1 2025 Revvity Earnings Conference Call. My name is Sammy, and I will be coordinating your call today.
Revvity (RVTY) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Revvity (RVTY) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Revvity (RVTY) Beats Q1 Earnings and Revenue Estimates
Revvity (RVTY) came out with quarterly earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $0.98 per share a year ago.
